Loading stock data…
$3.27-0.02 (-0.61%)
Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc. in the Healthcare sector is trading at $3.27 with a market capitalization of $489M. Wall Street consensus targets $10.75 (4 analysts), implying a +228.7% move over the next 12 months. The stock is currently near its 52-week low of $2.15, remaining 39.2% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$15.01M↑ | -$19.46M↑ | -$20.33M↓ | -$10.33M↓ | -$10.22M |
| Net Income | -$12.91M↑ | -$19.05M↑ | -$19.87M↓ | -$10.09M↓ | -$9.87M |
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clin...